Tigermed to snag top-end price for $1.4bn Hong Kong IPO
Hangzhou Tigermed Consulting is set to pocket HK$10.7bn ($1.38bn) from its Hong Kong secondary listing, with solid support from Chinese and global investors driving final pricing to the top of guidance.
Unlock this article.
The content you are trying to view is exclusive to our subscribers.
To unlock this article: